Laboratory validation of a low density lipoprotein apolipoprotein-B assay

Clinical Biochemistry

Volumn 47, Issue 16-17, 2014, Pages 211-215

  Kelsey, David E ^a   Toher, Jessica L ^a   Foster, Michael T ^b   Boulanger, James A ^b   Cervinski, Mark A ^b,c  

^a Maine Standards Company   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Apolipoprotein B; Assay validation; Atherosclerosis; Low density lipoprotein particle

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN;

BIOASSAY; PROCEDURES;

APOLIPOPROTEINS B; BIOLOGICAL ASSAY; LIPOPROTEINS, LDL;

EID: 84908698109     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.07.016     Document Type: Article

References (16)

1. Barter P.J., Ballantyne C.M., Carmena R., Castro Cabezas M., Chapman M.J., Couture P., et al. Apo-B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006, 259(3):247-258.
2. Virani S.S., Pompeii L., Lincoln A.E., Dunn R.E., Tucker A.M., Nambi V., et al. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis 2012, 222(2):551-556.
3. Kastelein J.J., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117(23):3002-3009.
4. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101(5):477-484.
5. Gigante B., Leander K., Vikstrom M., Frumento P., Carlsson A.C., Bottai M., et al. Elevated ApoB serum levels strongly predict early cardiovascular events. Heart 2012, 98(16):1242-1245.
6. Lamarche B., Tchernof A., Mauriege P., Cantin B., Dagenais G.R., Lupien P.J., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279(24):1955-1961.
7. Sniderman A., Vu H., Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991, 89(2-3):109-116.
8. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113(12):1556-1563.
9. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119(7):931-939.
10. Parish S., Offer A., Clarke R., Hopewell J.C., Hill M.R., Otvos J.D., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125(20):2469-2478.
11. Blake G.J., Otvos J.D., Rifai N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002, 106(15):1930-1937.
12. Cromwell W.C., Otvos J.D., Keyes M.J., Pencina M.J., Sullivan L., Vasan R.S., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study -implications for LDL management. J Clin Lipidol 2007, 1(6):583-592.
13. Cole T.G., Contois J.H., Csako G., McConnell J.P., Remaley A.T., Devaraj S., et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013, 59(5):752-770.
14. Marcovina S.M., Gaur V.P., Albers J.J. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein (a), and apolipoproteins A-1 and B. Clin Chem 1994, 40:586-592.
15. Markwell M.A.K., Haas S.M., Bieber L.L., Tolber N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978, 87:206-210.
16. Stone N.J., Robinson J.G., Lichtenstein A.H., Merz N.B., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014, 129:S1-S45.